Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jun 22, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
23.2%
-39.0% vs 52w high · -4.2% 1mo
Price (last ~year)
Novo Nordisk (NVO) posted TTM revenue of $327.80B, reflecting 24.0% year-over-year growth, alongside an 83.2% gross margin and 61.6% operating margin. The company is expanding the reach of its Wegovy pill into European markets and deepening its strategic focus on China, though analysts have flagged risks associated with a 2031 patent cliff. Trading at a 10.14 P/E, the firm is balancing this growth trajectory against recent cybersecurity challenges and mixed quarterly earnings results.
Valuation
- Market cap
- $191.24B
- P/E
- 10.14
- PEG
- 3.134
- P/B
- 6.06
- P/S
- 0.583
- EV/EBITDA
- 7.59
- Beta
- 0.349
- Analyst target
- $47.18
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $43.19
- 1-month
- -4.2%
- 3-month
- +21.1%
- RSI (14)
- 40
- vs SMA200
- -8.0%
- 52-wk position
- 23.2% -39.0% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Bullish GLOBALink | Novo Nordisk CEO: China is becoming more central to the company's global strategy · 2026-06-21
- Bullish Novo Nordisk Stock Climbs as Analyst Flags Potential for More Wegovy Pill Sales · 2026-06-19
- Bearish Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns · 2026-06-19
- Neutral Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures? · 2026-06-19
- Somewhat-Bullish Novo Nordisk Stock Jumps as Owner Launches Obesity Research Network · 2026-06-19
- Bearish Novo Nordisk Breach Exposes Software Development Pipeline Risk · 2026-06-18
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)